Michael Levinson, MD
Psychiatry · Burlingame, CANPI 1306876883
Payments from drug & device makers
Across 1,287 payments — averaging $52.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$28K
- Eisai Inc.$7K
- Livanova USA, Inc.$7K
- Sunovion Pharmaceuticals Inc.$4K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Neurocrine Biosciences, Inc.$3K
- plus $16K from 25 others
What the payments were for
- Consulting fees$6,52511%
- Speaking & faculty fees$23,44838%
- Travel & lodging$1,5172%
- Food & beverage$29,42848%
- Education$580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 162 | $27,537 |
| Eisai Inc. | 24 | $7,190 |
| Livanova USA, Inc. | 3 | $7,000 |
| Sunovion Pharmaceuticals Inc. | 258 | $4,308 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 107 | $2,979 |
| Neurocrine Biosciences, Inc. | 103 | $2,656 |
| Alkermes, Inc. | 89 | $2,483 |
| Lundbeck LLC | 92 | $2,217 |
| Takeda Pharmaceuticals U.S.A., Inc. | 61 | $1,654 |
| Otsuka America Pharmaceutical, Inc. | 80 | $1,637 |
| Vanda Pharmaceuticals Inc. | 49 | $1,356 |
| Teva Pharmaceuticals USA, Inc. | 18 | $1,082 |
| Axsome Therapeutics, Inc. | 20 | $738 |
| Indivior Inc. | 29 | $670 |
| E.r. Squibb & Sons, L.L.C. | 17 | $652 |
| Idorsia Pharmaceuticals US Inc | 28 | $592 |
| Corium, LLC | 25 | $553 |
| Jazz Pharmaceuticals Inc. | 26 | $468 |
| Johnson & Johnson | 13 | $395 |
| Merck | 14 | $296 |
| Bausch Health US, LLC | 12 | $287 |
| Adlon Therapeutics L.p. | 15 | $265 |
| Almatica Pharma LLC | 8 | $236 |
| Shire North American Group Inc | 9 | $209 |
| Ironshore Pharmaceuticals Inc. | 7 | $133 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $101 |
| Alfasigma USA, Inc. | 4 | $83 |
| Noven Therapeutics, LLC | 3 | $65 |
| Sumitomo Pharma America, Inc. | 4 | $58 |
| Pfizer | 2 | $48 |
| Avanir Pharmaceuticals, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$67,974 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 25 | $205,906 |
| RexultiBrexpiprazole | 45 | $73,873 |
| FanaptIloperidone | 22 | $66,271 |
| NamzaricMemantine Hcl/Donepezil Hcl | 67 | $45,117 |
| VraylarCariprazine Hcl | 27 | $37,700 |
| BelsomraSuvorexant | 57 | $29,964 |
| Lurasidone Hcl | 79 | $23,662 |
| TrintellixVortioxetine Hydrobromide | 27 | $17,505 |
| VyvanseLisdexamfetamine Dimesylate | 34 | $15,335 |
| Aripiprazole | 91 | $10,245 |
| LexaproEscitalopram Oxalate | 21 | $9,186 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 155 | $8,575 |
| Memantine Hcl ErMemantine Hcl | 55 | $8,385 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 51 | $7,824 |
| QuviviqDaridorexant Hcl | 11 | $5,374 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $2,656 | $205,90625 claims |
| AbbVieNamzaric, Vraylar, Lexapro | $27,537 | $92,003115 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,637 | $73,87345 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,356 | $66,27122 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $1,654 | $32,84061 claims |
| MerckBelsomra | $296 | $29,96457 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $592 | $5,37411 claims |
| Eisai Inc.Dayvigo | $7,190 | $4,65014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Burlingame
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.